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Summary.-The effect of combinations of the conventional chemotherapeutic agent
1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) and nitroimidazole radiation
sensitizers was evaluated in female C3H mice. Tumour response to single-agent or
combination therapy was assessed in a tumour growth-delay assay. In the KHT
sarcoma the simultaneous addition of misonidazole (MISO) was found to increase
significantly the tumour growth delayresultingfrom CCNU treatment. The observed
enhancement ratios (ER) increased with MISO dose, and ranged from 1x3 to 1-9 for
sensitizer doses of 0-25-1l0 mg/g. The combination of CCNU and 1-0 or 0-5mg/g
MISO in the RIF-1 tumour or the MT-1 tumour produced ERs of -2-0 and -15
respectively.
In the KHT sarcoma a series of other nitroimidazole sensitizers, including Ro-
05-9963, SR-2555, SR-2508 and metronidazole (METRO), were also evaluated at
equimolar doses (5 mmol/kg) in combination with a 20mg/kg dose of CCNU. Unlike
MISO, these compounds in general failed to enhance the CCNU cytotoxicity in this
tumour model. However, SR-2508 did enhance the response of the RIF-1 tumour to
large single doses of CCNU, though not as much as MISO.
Normal-tissue toxicity was determined using peripheral white blood cell (WBC)
counts 3 days after treatment. CCNU doses of 10-50 mg/kg given either alone or in
simultaneous combination with 0 5 or 1-0 mg/g MISO were studied. WBC toxicity
increased with CCNU dose, but the addition of MISO at either dose did not signifi-
cantly enhance this normal-tissue toxicity.
THERE HAS RECENTLY been considerable
interest in combining conventional chemo-
therapeutic agents and chemical radiation
sensitizers in the treatment of animal
tumour models. Such studies have been
initiated because of evidence from both
in vitro and in vivo tumour systems which
has suggested that hypoxic tumour cells
may be preferentially spared by some
anti-tumour agents such as 1,3-bis(2-
chloroethyl)-l-nitrosourea (BCNU) Adria-
mycin, and nitrogen mustard (Hill &
Stanley, 1975; Sutherland et al., 1978,
1979; Hill, 1979). Others have reported
that the addition of a radiation sensitizer
such as misonidazole (MISO) may enhance
the tumour-cell cytotoxicity of some
chemotherapeutic agents (Sutherland et
al., 1980; Rose et al., 1980; Clement et al.,
1980; Tannock, 1980a,b; Mulcahy et al.,
1981; Siemann, 1981; Law et al., 1981;
Twentyman, 1981). Depending on the
agents, treatment conditions and tumour
and normal tissue-response endpoints
chosen, such combinations maypotentially
lead to a therapeutic advantage (Rose
et al., 1980; Clement et al., 1980; Tannock,
1980a; Mulcahy et al., 1981; Siemann,
1981; Law et al., 1981).
Our laboratory has previously reported
on the effects of combination therapy
with nitrosoureas and MISO or Ro-
05-9963 (Mulcahy et al., 1981; Siemann,
1981). This class of anti-tumour agent
was chosen for combination with radio-
sensitizers because, at least in some murineINTERACTION OF CCNU WITH RADIATION SENSITIZERS
tumours, hypoxic cells have been shown
to be resistant to treatment with such
agents (Hill & Stanley, 1975). The present
study extends the previous investigations
combining CCNU and MISO, as well as
evaluating this chemotherapeutic agent
in combination with other nitroimidazole
sensitizers including Ro-05-9963, SR-2555,
SR-2508 and metronidazole (METRO).
Although experiments were performed
primarily with the KHT sarcoma, the
effect of combining CCNU and MISO also
was determined in the RIF-1 and MT-1
tumours for comparison.
MATERIALS AND METHODS
Animals and tumour systems.-In both
the tumour and normal-tissue toxicity studies
8-14-week-old female C3H/HeJ mice from
Jackson Laboratories (Bar Harbor, Maine)
were used. KHT sarcoma cells (Kallman et
at., 1967) were prepared from solid tumours
by mechanical dissociation (Thomson &
Rauth, 1974) and passaged in vivo every
2 weeks. RIF-1 tumour cells were maintained
and passaged alternately in vitro and in vivo,
as in the protocol ofTwentyman et al. (1980).
The first-generation mammary tumours
(MT-1) were obtained by injecting cells from
a frozen stock of a single-cell suspension
prepared from a spontaneously arising mam-
mary tumour (Siemann & Sutherland, 1980).
For experiments, 2 x 105 tumour cells
were injected i.m. in the left hind limb.
Once the tumours reached a size equivalent
to a weight of 0-2-0-3 g (see the section
headed "Tumour response") the mice were
allocated to groups which received no treat-
ment, the chemotherapeutic agent alone or
the combination of the chemotherapeutic
agent and the radiosensitizer.
Treatments.-CCNU was kindly provided
by Dr Robert Engle of the Developmental
Therapeutics Program, Division of Cancer
Treatment of the National Cancer Institute.
MISO was received from Dr Ven Narayanan
ofthe Drug Synthesis and Chemistry Branch,
National Cancer Institute. CCNU was dis-
solved in absolute ethanol (10 mg/ml) until
just before injection, when 9 ml of a 0.3%
solution of hydroxypropyl cellulose in sterile
saline was added to the stock solution. All
the radiation sensitizers were dissolved in
phosphate-buffered saline (PBS): MISO at
20 mg/ml, Ro-05-9963 at 40 mg/ml, SR-2508
and SR-2555 at 110 mg/ml, and METRO
at 10 mg/ml. All injections were by body wt
and all CCNU-sensitizer combinations were
given simultaneously. CCNU, MISO, Ro-
05-9963 and METRO were administered i.p.,
whilst the two SR sensitizers were given by
i.v. injections via the tail vein. Injecting
animals receiving CCNU with volumes of
PBS equal to those administered to mice
receiving a sensitizer in combination with
CCNU, did not affect the tumour response
to CCNU. Tumour growth also was not in-
fluenced by injecting mice only with the
CCNU carrier.
Tumour response.-Response to treatment
was assessed in a tumour growth-delay assay.
Followingthetreatment the animals' tumours
were measured daily by passing the tumour-
bearing legs through a plastic plate with
increasing-diameter holes (Siemann et al.,
1977). The smallest hole the tumour-bearing
leg would pass through was recorded, and
converted to a tumour weight using a calibra-
tion curve obtained by excising and weighing
the tumours oftumour-bearing legs ofvarious
sizes (Siemann et al., 1977; Siemann & Suther-
land, 1980). The time for each tumour in
each group to grow to 4 or 5 times the starting
size was then recorded. In these studies,
particularly in those groups receiving the
sensitizer-chemotherapeutic agent combina-
tions, a considerable range of tumour re-
sponses was found. Sometimes animals had
to be killed for humane reasons before the
tumours of others in the same treatment
group reached the desired endpoint size.
The use of mean tumour weights, therefore,
was felt to be inappropriate, and the median
time to reach 4-5 times the initial size was
used for each group. Confidence intervals
about the median were calculated using
non-parametric statistics (Noether, 1971).
Peripheral white blood cell (WBC) toxicity.-
Peripheral WBC counts were determined
from 10,ul samples taken from the tail
veins of tumour- or non-tumour-bearing
female C3H/HeJ mice. Before counting, the
sample was diluted in 10 ml saline and the
red blood cells lysed by adding RBC lysing
agent. Counts were made on a Coulter Counter
and Channelyzer system (Model C1000).
Blood smears were also made. The smears
were air-dried and stained with Wright's
Giemsa stain. After staining, 200 cells/
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slide were counted and scored as granulo-
cytes, lymphocytes or monocytes.
Studies with CCNU indicated a nadir in the
number of white cells in the peripheral blood
3 days after treatment, as reported by others
(Anderson et al., 1975). In addition, the
combination of CCNU+MISO produced a
peripheral WBC minimum 2-4 days after
injection. Consequently the effect of com-
bining MISO at doses of 0-5 or 1-0 mg/g
with CCNU over a range of CCNU doses
was evaluated on Day 3.
RESULTS
The response of KHT sarcomas to
CCNU alone or in combination with
MISO is shown in Fig. 1. The data in the
left panel indicate that, at every dose of
CCNU, the addition of a 1-0 mg/g dose
of MISO significantly enhanced the tum-
our-growth delay. Reducing the dose of
the sensitizer administered with this
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nitrosourea reduced the growth-delay
enhancement (right panel). However, even
at the lower doses of MISO (0.5 or 0-25
mg/g) there was a considerable improve-
ment in tumour response to CCNU. The
resultant enhancement ratios (ERs), de-
fined as the dose of CCNU alone divided
by the dose of CCNU+MISO to cause a
given tumour effect, were determined for
a CCNU dose of 30 mg/kg, and were found
to be -1-9, 1-7 and 1-3 for MISO
doses of 1-0, 0-5 and 0-25 mg/g respec-
tively.
For comparison, the effect of combin-
ing CCNU and MISO also was assessed
in a first-generation transplanted mam-
mary tumour (MT-1) and the RIF-1
tumour (Fig. 2). Boththese tumour models
grow at a slower rate, and are considerably
more resistant to treatment with CCNU
than the KHT sarcoma. For example,
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FiG. 1. Median time to grow to 4 x the starting size as a function ofthe CCNU dosefor KHT sarcoma-
bearing mice treated with CCNU alone (*), or CCNU plus either 1*0 mg/g (0), 0 * 5 mg/g (LO) or
0* 25 mg/g (*) MISO respectively. Each data point represents the median tumour response ( ± 97%
confidence limits) on pooling the results of 2-4 experiments, each using 7-9 mice. The dashed curves
in the right-hand panel are the curves for CCNU alone and CCNU + *0 mg/g MISO (from left
hand panel) redrawn for comparison.
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FIG. 2. The response of the AMT-I andl RIF-I tumours to combinations of CCNU and MISO.
Solid symbols show the results for CCNU alone, wlilst the open symbols indicate the effect of com-
bining 0-5 or 1 -0 mg/g MISO with CCNU in the MT-I and RIF-1 tumours respectively. Different
shapes represent different experiments. Data slhown are the median tumour responses (+ 98%
confidence limits) of 7-10 mice.
TABLE I. The Response of the KHT sar-
coma to sirnultaneous combinations of a
20mg/ky dose of CCNU and a 5mmol/kg
dose of different nitroimidazole radio-
sensitizers*
Aledian time ((lays) to reach
4 x starting size (970O
Treatment confidence limits)t
Saline 12 - 5 (10- 5-16)
Ro-05-9963 14 (1 3-15)
Ro-05-9963 13 - 5 (11- 5-15)
(3 li after CCNU)
METRO 12 (10 5-14)
SR-2508 13-5 (12-15)
SR-2555 14 5 (13-16)
MISO 23 (21- 5-27)
* The data slhown are the pooled results of 2-4
experiments eaclh using 7-9 mice, except the CCNU-
METRO combination, which was a single experiment.
t Calculated using non-parametric statistics on
samples of 9-28 mice.
whereas a 30 mg/kg dose of this nitro-
sourea leads to a tumour growth delay of
14 days in the KHT sarcoma, such a
treatment delays tumour growth by only
1 2 and - 3 days in the MT-I and RIF-1
tumours respectively. Despite the greater
resistance to CCNU in these two tumour
models, MISO effectively enhance the
tumour response to this chemotherapeutic
agent. The ERs calculated for CCNU
combined either with 0 5 mg/g MISO in
the MT-1 tumour (- 1 5) or I 0 mg/g
MISO in the RIF-1 tumour (- 2 0) were
found to be very similar to those obtained
in the KHT sarcoma (Fig. 1).
In order to determine whether other
commonly studied nitroimidazole sensi-
tizers could mimic in the KHT sarcoma
the enhanced tumour response to CCNU
observed by the addition of MISO, the
radiosensitizers metronidazole (METRO),
Ro-05-9963, SR-2508 and SR-2555 in
combination with CCNU also were studied
in this tumour. Table I shows the response
of KHT sarcomas to a single 20 mg/kg
dose of CCNU combined with a 5 mmol/kg
dose of the various sensitizers evaluated.
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FIG. 3.-The effect of combining 5*0 mmol/
kg SR-2508 and CCNU inthe RIF- I tumour
system. The data from 2 experiments are
shown (OJ, A). Similarly shaped symbol.s
are from experiments done concurrently.
The dashed curves and the CCNU (0, *A)
or CCNU+MISO (O, A) results are taken
from Fig. 2 and shown for comparison.
Each data point represents the median
tumour response (±+ 98% confidcence limits)
on a group of 7 mice.
In general the chemotherapeutic agent
and the radiosensitizer were administered
simultaneously, though the effect of ad-
ministering Ro-05-9963 3 h after CCNU
was also studied. This latter interval was
based on the previous observation by
Mulcahy et al. (1981) which indicated
that giving this sensitizer 3 h after BCNU
led to a greater reponse in the KHT
sarcoma than to BCNU alone. The findings
showed that, in contrast to MISO these
other sensitizers showed no siginficant
enhancement when combined with 20 mg/
kg CCNU, in terms of KHT t'umour-
growth delay. Similar observations have
recently been made by others (Workman
& Twentyman, 1982).
Fig. 3 illustrates results in the RIF-1
tumour for CCNU combined with SR-
2508 at the same equimolar dose as MISO
(5mmol/kg). The data indicatethat, unlike
MISO, SR-2508 improves the tumour
response to CCNU only at the largest
doses of CCNU.
To assess normal-tissue toxicity, WBC
counts were made on blood samples
taken from the tails of C3H mice. In the
initial investigation, WBC counts after
treatment with single doses of 1 mg/g
MISO, 20 mg/kg CCNU or their simul-
taneous combination were taken from
non-tumour-bearing mice at various time
intervals up to 28 days. The data showed
that CCNU and CCNU+MISO treatments
reduced WBC counts between Days 2
and 4, followed by recovery. The results
on Day 3 are illustrated by the squares
in Fig. 4. In this experiment the com-
bination of agents led to a WBC drop
which was more severe and lasted longer
than that with CCNU alone. Differential
counts indicated that the leucocytes
most affected by the single agent or the
combination were the peripheral granulo-
cytes, and that the nadir in these differ-
ential cell counts mirrored that seen in
the total WBC counts. Little enhance-
ment in kill of lymphocytes (compared
to CCNU alone) was observed when
MISO was added to the CCNU. These
findings were similar to previous reports
on nitrosourea effects on WBC numbers
in mice (Anderson et al., 1975). So Day
3, which showed a nadir for the single-
dose CCNU treatments as well as for the
CCNU-MISO combination, was chosen
forsubsequent WBC toxicity evaluations.
Fig. 4 shows total WBC counts 3 days
after treatment with a range of CCNU
doses given alone or simultaneously with
either 1 0 or 0-5 mg/g MISO. The data
indicate that, unlike the findings in the
previously described preliminary study,
when complete dose-response curves for
CCNU and CCNU+MISO were obtained,
276INTERACTION OF CCNU WITH RADIATION SENSITIZERS
10
0 10 20 30 40 50 0 10 20 30 40 50
CCNU dose (mg/kg)
FIG. 4.-Total WBC counts as a function of the CCNU dose measured 3 days after treatment with
CCNU alone (solid symbols) or CCNU+ O* 5 mg/g MISO (harlequin symbols) or CCNU+ 1* 0 mg/g
MISO (open symbols). Different shapes represent different experiments. Each data point is the mean
+ s.d. of a sample of 5 mice.
TABLE II.-The enhancing #
on the cytotoxicity of CC0
and normal tissues
Tumour models
KHT sarcoma
MT-1 mammary
tumour
RIF-1 tumour
Normal tissues
Gut
Marrow
Endpoints
Clonogenic cell
survival
Tumour growth
delay
Tumour growth
delay
Tumour growth
delay
LD50/7
Peripheral
WBC
effect of MISO combination therapy with CCNU and
NTU in tumour MISO for tumour responses and normal-
tissue toxicities in the present study, as
MISO well as in a previous report (Siemann,
dose approx. 1981). The data indicate less enhance-
(mg/g) ER ments of CCNU toxicity by addition of
0 25 1.9* MISO for endpoints of peripheral WBC
100 2.1* numbers than for gut lethality. It should
0 25 1 3 be noted, however, that, in mice, gut
0°5 1 7 toxicity is probably the more relevant
1 .0 1P9is
05 1.5 factor defining single-dose nitrosourea
toxicity (Blackett et al., 1975). The tum- 1o0 2 0 our-response modification by the CCNU-
MISO combination in general was larger
0°5 1.2* than the modification in the normal tissue.
10 1.4* This enhancement appears to be very 0.5 o30
1.0 1.0 similar in the 3 tumour models studied.
* Siemann (1981).
there was no consistent enhancement of
CCNU-induced WBC toxicity by MISO.
This was especially so for CCNU+ 05
mg/g MISO (right-hand panel).
Table II summarizes the results of
19
DISCUSSION
Combinations of the nitroimidazole
radiation sensitizer MISO and conven-
tional chemotherapeutic agents such as
cyclophosphamide (CY), BCNU, CCNU
and melphalan (L-PAM) have been shown
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to enhance tumour cytotoxicity in vivo
(Clement et al., 1980; Rose et al., 1980;
Tannock, 1980b; Mulcahy et al., 1981;
Siemann, 1981; Law et al., 1981; Twenty-
man, 1981). As has been reported pre-
viously (Siemann, 1981), the combination
of CCNU with MISO was particularly
effective in the KHT sarcoma. The
investigation of this combination has
been extended in the present study, and
tumour growth-delay dose-response
curves for CCNU doses combined with a
range of MISO doses were obtained (Fig.
1). The results indicated that MISO could
enhance the response ofthe KHT sarcoma
to single doses of CCNU, even when the
MISO dose was as low as 0-25 mg/g.
This observation was qualitatively similar
to the previous finding in the KHT sar-
coma using a clonogenic-cell survival
assay (Siemann, 1981). However, in that
investigation larger ERs were obtained
than in the present report using tumour-
growth delay as the endpoint (Table II).
Larger ERs for BCNU+MISO have also
been observed in our laboratories when
tumour response was assessed by in vivo
to in vitro clonogenic-cell survival than
using in situ tumour growth delay (Mul-
cahy et al., submitted). Such apparent dis-
crepancies between these two assays are
not uncommon, and have previously
been observed by many other authors
studying the effects of a variety of treat-
ments including radiation, chemotherapy,
or combined-modality therapies on tum-
our response (Stephens & Peacock, 1977;
Begg et al., 1980; McNally & de Ronde,
1980; Twentyman, 1980; Hill, 1980).
In order to determine whether the
enhanced tumour responses to CCNU-
MISO combinations were specific to the
KHT sarcoma, the effect of such treat-
ments also were evaluated in the RIF-1
tumour as well as in a first-generation
transplanted mammary tumour. Even
though CCNU alone was found to be less
effective in these two systems than in the
KHT tumour, the relative ERs on the
addition of MISO were similar (Fig. 2 and
Table II).
Since other nitroimidazole sensitizers
have been used or considered for clinical
application, their ability to enhance to
toxicity of CCNU also was tested. For
comparison, these sensitizers were com-
bined with CCNU at the same mmol/kg
dose as MISO. Complete dose-response
curves were not determined, yet even the
single-dose combinations (Table I) indi-
cated that, when administered simul-
taneously with CCNU, MISO was clearly
superior to METRO, Ro-05-9963, SR-
2508 and SR-2555 in enhancing the
efficacy of CCNU in the KHT sarcoma.
However, the data in Fig. 3 showed that
in the RIF-1 tumour, SR-2508 also en-
hanced the effect of CCNU, though only
for large CCNU doses. These results for
different nitroimidazole sensitizers clearly
require further investigation.
As we have suggested previously (Mul-
cahy et al., 1981; Siemann, 1981), the
enhancement of tumour response to alky-
lating chemotherapeutic agents by nitro-
imidazole sensitizers could be due to: (1)
cytotoxicity of sensitizer in cells spared
by the anti-tumour agents, (2) altered
drug pharmacokinetics, (3) sensitization
of the tumour to the chemotherapeutic
agent by the sensitizer, and (4) inhibition
of the repair of the chemotherapeutic
agent's potentially lethal damage (PLD)
by the sensitizer.
The first possibility appears highly
unlikely, since MISO causes no tumour-
growth delay and minimal cell kill in the
KHT sarcoma until doses in excess of
1 mg/g are administered (Mulcahy et al.,
1981a, submitted; Siemann, 1981). Yet
even doses as low as 0-25 and 0-5 mg/g of
this sensitizer can enhance considerably
the tumour response to CCNU (Table II).
With respect to the altered-pharmaco-
kinetics hypothesis, results to date are
conflicting. Findings in our laboratory
with a related nitrosourea (BCNU) and
CY have indicated that the MISO phar-
macokinetics are not altered when these
two agents are combined with this sensi-
tizer. Also, the addition of MISO has been
shown not to alter the pharmacokinetics
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of BCNU in mice (Tannock, 1980b) or
in patients (Urtasun et al., 1982).
Similar studies on the in vivo pharmaco-
kinetics of CCNU in the presence or ab-
sence of MISO do not exist. However,
since CCNU, unlike BCNU, undergoes
ring hydroxylation by liver microsomal
enzymes (May et at., 1974; Hilton &
Walker, 1975; Wheeler et al., 1977) the
possibility arises that the enhanced tum-
our response on the addition of MISO to
CCNU treatment could be the result of
altered CCNU metabolism in the presence
of the sensitizer. The observations in the
KHT sarcoma could be interpreted as
supporting this view, since MISO, which
undergoes oxidative demethylation, prob-
ably by liver microsomal mixed-function
oxidases, enhances the cytotoxicity of
CCNU, whereas Ro-05-9963 and SR-2508
are not metabolized in this manner (White
et al., 1980) and are relatively ineffective
(Table I). However, other have shown
that hydroxylation of the cyclohexane
ring of CCNU leads to metabolites which
have slightly better therapeutic indices
(Wheeler et al., 1977) or tumour efficacies
similar (Johnston et al., 1975) to that of
the parental CCNU. In addition, while
an enhanced rate of CCNU metabolism
has been reported in phenobarbital-pre-
treated animals (Hilton & Walker, 1975)
such treatments did not alter significantly
CCNU anti-tumour activity (Levin et al.,
1979). However, preliminary data in this
laboratory (Siemann, unpublished) have
indicated that phenobarbital pretreat-
ment can reduce, by about the same
factor, both the response of the KHT
sarcoma and the degree of normal-tissue
toxicity due to CCNU administration.
Also, Workman & Twentyman (1982),
have shown that SKF-525A, an
inhibitor of drug-metabolizing enzymes,
can enhance the tumoricidal effects of
CCNU. Finally, in contrast to the results
obtained with MISO, the 5-nitroimidazole
METRO, whichundergoes oxidative meta-
bolism (Ings et at., 1966), did not enhance
the response of the KHT sarcoma to
CCNU. In addition, SR-2508 effectively
enhanced the efficacy ofCCNU in the RIF-
1 tumour (Fig. 3), though only at the
largest doses of CCNU. Thus, whilst
altered chemotherapeutic-agent meta-
bolism may not be the primary mechanism
for the enhanced tumour response to
CCNU-sensitizer combinations, further
evaluation of the interactions between
anti-tumour agents and sensitizers is
clearly required.
Sensitization of the tumour cells to the
chemotherapeutic agent, perhaps analog-
ous to sensitization to radiation ofhypoxic
cells, is another possible mechanism of the
sensitizer effect. In support of this view,
Tannock (1980b) has shown that, whilst
the serum of mice treated with BCNU or
BCNU+MISO was equally toxic to cells
exposed in vitro under aerobic conditions,
the combination was much more toxic
to anaerobic cells. The present results
yield little information about this possible
mechanism. However, other studies
(Siemann & Mulcahy, 1982) have indi-
cated that, depending on the chemo-
therapeutic agent used, the enhanced
tumour response to MISO-chemothera-
peutic-agent combinations may result both
from a potentiation of the chemothera-
peutic agent's cytotoxic effects and/or an
inhibition of the clonogenic-cell recovery,
measured as a function of time after
treatment. When CCNU and MISO were
combined, the major effect of the sensi-
tizer appeared to be on the recovery in
clonogenic-cell survival, such that 24 h
after treatment tumour-cell survival in
mice receiving the combination treatment
was about 2% of that in mice given only
CCNU. Similar cell-survival responses
have also been observed by Law et al.
(1981) for combinations of CY and MISO
in the RIF-1 tumour. Thus, although the
present investigation does not allow us
to determine the mechanism of the
enhanced tumour response with certainty,
other data suggest that inhibition of
recovery of clonogenic-cell survival plays
a major role in the large ERs observed
with the CCNU-MISO combination in
the KHT sarcoma.
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It is of interest to note that, unlike
MISO, the other sensitizers evaluated
in combination with 20 mg/kg CCNU were
ineffective in the KHT sarcoma (Table I).
At an equimolar dose, SR-2508 did
enhance the response ofthe RIF-1 tumour
to CCNU, though not to the same extent
as MISO, and not at all at lower doses
of CCNU (Fig. 3). Enhancement of CY
damage by SR-2508 has also been
found in the RIF-1 tumour (Law et al.,
1981) and KHT sarcoma (Siemann &
Sutherland, 1982). These findings imply
that there may be some degree of
both tumour and chemotherapeutic-agent
specificity when different radiosensitizers
are used to modify the tumoricidal action
of anti-tumour agents.
Experiments in our laboratories with
nitrosoureas of different alkylating and
carbamoylating activities, have also shown
that the particular nitrosourea chosen
may be a key factor in the level of en-
hancement of tumour-cell kill on the
addition of MISO. Of the nitrosoureas
studied, CCNU, which was the most car-
bamoylating agent tested, gave the largest
enhancement ratio when combined with
MISO. In contrast, the addition ofMISO to
chlorozotocin, anitrosoureawithrelatively
little carbamoylating activity, had no
effect (Mulcahy et al., submitted). Further
evaluations of various nitrosoureas and
radiation sensitizers invitro areinprogress.
Finally the question of enhanced
therapeutic gain needs to be considered.
Using gut toxicity and depression of
WBC numbers as endpoints, investiga-
tions in this laboratory have indicated
a greater effect in the tumour than the
normal tissues when CCNU and MISO
are combined. These findings imply that
an improved therapeutic result may be
achieved through such a combination.
Nevertheless, the extension of combina-
tions of chemotherapeutic agents and
radiation sensitizers to the clinic should
be done cautiously.
The investigations reported in this paper were
supported by NIH Grants CA-11051, CA-20329 and
CA-11198. Excellent technical assistance was pro-
vided by J. Beilman. This work was presented in
part at the 29th Annual Meeting of the Radiation
ResearchSociety, June 1981,Minneapolis, Minnesota.
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